» Articles » PMID: 36875092

Altered Lipid Metabolites Accelerate Early Dysfunction of T Cells in HIV-infected Rapid Progressors by Impairing Mitochondrial Function

Overview
Journal Front Immunol
Date 2023 Mar 6
PMID 36875092
Authors
Affiliations
Soon will be listed here.
Abstract

The complex mechanism of immune-system damage in HIV infection is incompletely understood. HIV-infected "rapid progressors" (RPs) have severe damage to the immune system early in HIV infection, which provides a "magnified" opportunity to study the interaction between HIV and the immune system. In this study, forty-four early HIV-infected patients (documented HIV acquisition within the previous 6 months) were enrolled. By study the plasma of 23 RPs (CD4 T-cell count < 350 cells/µl within 1 year of infection) and 21 "normal progressors" (NPs; CD4 T-cell count > 500 cells/μl after 1 year of infection), eleven lipid metabolites were identified that could distinguish most of the RPs from NPs using an unsupervised clustering method. Among them, the long chain fatty acid eicosenoate significantly inhibited the proliferation and secretion of cytokines and induced TIM-3 expression in CD4 and CD8 T cells. Eicosenoate also increased levels of reactive oxygen species (ROS) and decreased oxygen consumption rate (OCR) and mitochondrial mass in T cells, indicating impairment in mitochondrial function. In addition, we found that eicosenoate induced p53 expression in T cells, and inhibition of p53 effectively decreased mitochondrial ROS in T cells. More importantly, treatment of T cells with the mitochondrial-targeting antioxidant mito-TEMPO restored eicosenoate-induced T-cell functional impairment. These data suggest that the lipid metabolite eicosenoate inhibits immune T-cell function by increasing mitochondrial ROS by inducing p53 transcription. Our results provide a new mechanism of metabolite regulation of effector T-cell function and provides a potential therapeutic target for restoring T-cell function during HIV infection.

Citing Articles

HIV and the gut microbiome: future research hotspots and trends.

Wu Z, Xie Z, Cui X, Sun X, Zhao F, Wang N Front Microbiol. 2025; 16:1466419.

PMID: 39990153 PMC: 11844347. DOI: 10.3389/fmicb.2025.1466419.


Examining Chronic Inflammation, Immune Metabolism, and T Cell Dysfunction in HIV Infection.

Mu W, Patankar V, Kitchen S, Zhen A Viruses. 2024; 16(2).

PMID: 38399994 PMC: 10893210. DOI: 10.3390/v16020219.

References
1.
Fenwick C, Joo V, Jacquier P, Noto A, Banga R, Perreau M . T-cell exhaustion in HIV infection. Immunol Rev. 2019; 292(1):149-163. PMC: 7003858. DOI: 10.1111/imr.12823. View

2.
Dalmau J, Rotger M, Erkizia I, Rauch A, Reche P, Pino M . Highly pathogenic adapted HIV-1 strains limit host immunity and dictate rapid disease progression. AIDS. 2014; 28(9):1261-72. DOI: 10.1097/QAD.0000000000000293. View

3.
Asarat M, Apostolopoulos V, Vasiljevic T, Donkor O . Short-Chain Fatty Acids Regulate Cytokines and Th17/Treg Cells in Human Peripheral Blood Mononuclear Cells in vitro. Immunol Invest. 2016; 45(3):205-22. DOI: 10.3109/08820139.2015.1122613. View

4.
Vasan K, Werner M, Chandel N . Mitochondrial Metabolism as a Target for Cancer Therapy. Cell Metab. 2020; 32(3):341-352. PMC: 7483781. DOI: 10.1016/j.cmet.2020.06.019. View

5.
Alrubayyi A, Moreno-Cubero E, Hameiri-Bowen D, Matthews R, Rowland-Jones S, Schurich A . Functional Restoration of Exhausted CD8 T Cells in Chronic HIV-1 Infection by Targeting Mitochondrial Dysfunction. Front Immunol. 2022; 13:908697. PMC: 9295450. DOI: 10.3389/fimmu.2022.908697. View